Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 2/2024

Open Access 10-02-2024 | Hepatitis B | Review

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Authors: Harish Gopalakrishna, Marc G. Ghany

Published in: Current Hepatology Reports | Issue 2/2024

Login to get access

Abstract

Purpose of Review

Advancements in our understanding of the hepatitis B viral (HBV) life cycle have paved the way for novel approaches to treat HBV infection. This review summarizes the various strategies being pursued to achieve a functional cure, defined as loss of hepatitis B surface antigen (HBsAg) and absence of viral replication 6 months off-therapy.

Recent Findings

Direct acting antiviral, host targeting antiviral, and immunological approaches are in various stages of development as treatment for chronic HBV infection.

Summary

Novel treatments are being developed in pursuit of a cure for HBV. Current evidence suggests a single therapeutic agent alone may be insufficient, necessitating the need for combination therapy targeting HBV and the host immune response. Ongoing research focused on identifying the best therapeutic combination holds promise in achieving functional cure for HBV.
Literature
1.
2.
Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17(9):533–42.PubMedPubMedCentralCrossRef
3.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.PubMedCrossRef
4.
Ghany MG. Current treatment guidelines of chronic hepatitis B: the role of nucleos(t)ide analogues and peginterferon. Best Pract Res Clin Gastroenterol. 2017;31(3):299–309.PubMedCrossRef
5.
• Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39(10):1868–75. Seminal paper which showed long term safety and efficacy of Tenofovir in treatment of hepatitis B.PubMedCrossRef
6.
Chen CH, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN, et al. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatol Int. 2020;14(3):317–25.PubMedCrossRef
7.
Hirode G, Choi HSJ, Chen CH, et al. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology. 2022;162(3):757-771.e4.PubMedCrossRef
8.
Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol. 2020;18(2):457-67.e21.PubMedCrossRef
9.
• Yardeni D, Chang KM, Ghany MG. Current best practice in hepatitis B management and understanding long-term prospects for cure. Gastroenterology. 2023;164(1):42-60.e6. Comprehensive review on chronic hepatitis B management.PubMedCrossRef
10.
11.
Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. J Hepatol. 2017;67(4):847–61.PubMedCrossRef
12.
Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. Hepatology. 2023;78(5):1654-1673.
13.
Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology. Published online November 12, 2019.
14.
• Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70(3):361–70. Important study which showed HBsAg seroclearance was associated with decreased HCC risk.PubMedCrossRef
15.
Alawad AS, Auh S, Suarez D, Ghany MG. Durability of spontaneous and treatment-related loss of hepatitis B s antigen. Clin Gastroenterol Hepatol. 2020;18(3):700-9 e3.PubMedCrossRef
16.
Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections. J Hepatol. 2021;75(3):706–17.PubMedCrossRef
17.
Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol. 2013;11(8):1004-10 e1.PubMedCrossRef
18.
•• Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schluep T, Xu Z, Lanford RE, Lewis DL. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017 Sep 27;9(409):eaan0241. Important paper which showed that source of HBsAg is not only from cccDNA but also from integrated HBV DNA.
19.
Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023.
20.
Gane E, Locarnini S, Lim TH, Strasser S, Sievert W, Cheng W, et al. Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors. J Hepatol. 2021;75:S289–90.
21.
Agarwal K, Yuen MF, Wedemeyer H, Arizpe A, Shen L, Cloutier D, et al. Rapid HBsAg reduction in chronic hepatitis B virus infection: preliminary results from a PHASE 1 study evaluating a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody. Hepatology. 2021;74:514a-a.
22.
23.
Yuen MF, Berliba E, Sukeepaisarnjaroen W, Strasser S, Tangkijvanich P, Holmes J, et al. Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression. J Hepatol. 2021;75:S203–4.
24.
Yuen MF, Lim YS, Cloutier D, Thanawala V, Shen L, Elie SE, et al. Preliminary 48-week safety and efficacy data of Vir-2218 alone and in combination with pegylated interferon alfa in participants with chronic HBV infection. Hepatology. 2022;76:S19–20.
25.
• Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu CP, Stepanova T, Asselah T, Diaconescu G, Yim HJ, Heo J, Janczewska E, Wong A, Idriz N, Imamura M, Rizzardini G, Takaguchi K, Andreone P, Arbune M, Hou J, Park SJ, Vata A, Cremer J, Elston R, Lukić T, Quinn G, Maynard L, Kendrick S, Plein H, Campbell F, Paff M, Theodore D; B-Clear Study Group. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. N Engl J Med. 2022 Nov 24;387(21):1957-1968. Phase 2 trial showing effectiveness of bepirovirsen in management of hepatitis B.PubMedCrossRef
26.
Zhang H, Wang F, Zhu X, Chen Y, Chen H, Li X, et al. Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection. Clin Infect Dis. 2021;73(2):175–82.PubMedCrossRef
27.
Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology. 2020;159(2):521-+.PubMedCrossRef
28.
Zhang W, Guo L, Liu H, Wu G, Shi H, Zhou M, et al. Discovery of Linvencorvir (RG7907), a hepatitis B virus core protein allosteric modulator, for the treatment of chronic HBV infection. J Med Chem. 2023;66(6):4253–70.PubMedCrossRef
29.
Jia H, Mai J, Wu M, Chen H, Li X, Li C, et al. Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial. BMC Med. 2023;21(1):98.PubMedPubMedCentralCrossRef
30.
Gao Y, Kong F, Song X, Shang J, Yao L, Xia J, et al. Pradefovir treatment in patients with chronic hepatitis B: week 24 results from a multicenter, double-blind, randomized, noninferiority, phase 2 trial. Clin Infect Dis. 2021.
31.
Zhang H, Hu Y, Wu M, Liu J, Zhu X, Li X, et al. Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection. Aliment Pharmacol Ther. 2021;53(2):243–52.PubMedCrossRef
32.
Squires KE, Ogilvie L, Jucov A, Anastasiy I, Ghicavii N, Huguet J, et al. A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection. J Viral Hepat. 2023;30(1):19–28.PubMedCrossRef
33.
Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180–94.PubMedCrossRef
34.
Gane E, Dunbar PR, Brooks A, Zhao Y, Tan S, Lau A, et al. Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study. J Hepatol. 2020;73:S52-S.CrossRef
35.
Wang GQ, Qian JD, Cui YM, Yan YM, He HD, Wu JZ. A phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (ENVAFOLIMAB) in patients with chronic hepatitis B. Hepatology. 2021;74:62a-a.
36.
Ma H, Lim TH, Leerapun A, Weltman M, Jia J, Lim YS, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. JHEP Rep. 2021;3(6):100361.PubMedPubMedCentralCrossRef
37.
Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147(1):48–64.PubMedCrossRef
38.
Hehle V, Beretta M, Bourgine M, Ait-Goughoulte M, Planchais C, Morisse S, et al. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. J Exp Med. 2020;217(10).
39.
Vir Biotechnology announces first patient dosed in new phase 2 chronic hepatitis B virus trial evaluating combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI [press release]. 2023.
40.
Vaillant A. Oligonucleotide-based therapies for chronic HBV infection: a primer on biochemistry, mechanisms and antiviral effects. Viruses. 2022;14(9).
41.
Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, et al. RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection. Hepatology. 2020;72(1):19–31.PubMedCrossRef
42.
Gane E, Lim YS, Cloutier D, Shen L, Cathcart A, Ding X, et al. Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results. J Hepatol. 2021;75:S287–8.
43.
Yuen MF, Berliba E, Kim YJ, Holmes JA, Lim YS, Strasser SI, et al. Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection. Hepatology. 2020;72:62a-a63.
44.
Yuen MFHJ, Strasser SI, Leerapun A, et al. Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy. AASLD 2022; Washington. 2022.
45.
Gane E, Jucov A, Dobryanska M, Yoon KT, Lim TH, Arizpe A, et al. Safety, tolerability, and antiviral activity of the siRNA VIR-2218 in combination with investigational Ineutralizing monoclonal antibody VIR-3434 for the treatment of chronic hepatitis B virus infection: preliminary results from the phase 2 March trial. Hepatology. 2022;76:S18–9.
46.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(9):790–802.PubMedCrossRef
47.
Agarwal K, Lok J, Gane E. Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: opportunities and challenging the orthodoxy. J Hepatol. 2022;77(4):906–8.PubMedCrossRef
48.
Gane E, Yuen MF, Kim DJ, Chan HL, Surujbally B, Pavlovic V, et al. Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B. Hepatology. 2021;74(4):1795–808.PubMedCrossRef
49.
Yuen MF, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol. 2022;77(4):967–77.PubMedCrossRef
50.
Yan Z, Wu D, Hu H, Zeng J, Yu X, Xu Z, et al. Direct inhibition of hepatitis B e antigen by core protein allosteric modulator. Hepatology. 2019;70(1):11–24.PubMedCrossRef
51.
52.
Yuen MF, Zhou X, Gane E, Schwabe C, Tanwandee T, Feng S, et al. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol. 2021;6(9):723–32.PubMedCrossRef
53.
Gane EJ, Schwabe C, Berliba E, Tangkijvanich P, Jucov A, Ghicavii N, et al. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother. 2022;77(4):1102–10.PubMedPubMedCentralCrossRef
54.
Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, et al. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020;5(2):152–66.PubMedCrossRef
55.
Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, et al. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. J Hepatol. 2022;77(5):1265–75.PubMedCrossRef
56.
Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3–778 in patients with chronic HBV infection. Gastroenterology. 2019;156(5):1392-403.e7.PubMedCrossRef
57.
Gane EJ, Yuen M, Jucov A, Le K, Westland C, Schwabe C, et al. Safety, pharmacokinetics (pk), and antiviral activity of the capsid assembly modulator (Cam) Alg-000184 in subjects with chronic hepatitis B (Chb). Hepatology. 2021;74:516a-a517.
58.
Cai DW, Evanhcik M, Yan R, Kumar R, Zong YH, Huang Q, et al. Second generation hepatitis B virus core inhibitors ABI-H2158 and ABI-H3733 have enhanced potency and target coverage for both antiviral inhibition and covalently closed circular DNA establishment activities. J Hepatol. 2021;75:S290-S.
59.
Gane EJ, Jucov A, Kolomiichuk L, Eley T, Brown J, King Y, et al. Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB). J Hepatol. 2022;77:S848–9.CrossRef
60.
61.
Agarwal K, Buti M, van Bömmel F, et al. Efficacy and safety of combination treatment with siRNA JNJ-73763989 and capsid assembly modulator JNJ-56136379 (bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B patients: Follow-up week 48 end of study results from REEF-2. American Association for the Study of Liver Diseases (AASLD) Liver Meet. 2022;4–8 (abstr 5012).
62.
Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–84.PubMedCrossRef
63.
Yardeni D, Ghany MG. Review article: hepatitis B—current and emerging therapies. Aliment Pharmacol Ther. 2022;55(7):805–19.PubMedCrossRef
64.
Cai DW, Mills C, Yu WQ, Yan R, Aldrich CE, Saputelli JR, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012;56(8):4277–88.PubMedPubMedCentralCrossRef
65.
Wang L, Zhu Q, Zhang JD, Zhang Y, Ni X, Xiang K, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2023;78(4):742–53.PubMedCrossRef
66.
Mouzannar K, Fusil F, Lacombe B, Ollivier A, Menard C, Lotteau V, et al. Farnesoid X receptor-alpha is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo. FASEB J. 2019;33(2):2472–83.PubMedCrossRef
67.
Scalfaro P, Heo J, Liu CJ, Hsu CW, Chuang WL, Hu TH, et al. A phase 2 study testing FXR agonist vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results. J Hepatol. 2021;75:S761–2.
68.
Kostyushev D, Brezgin S, Kostyusheva A, Zarifyan D, Goptar I, Chulanov V. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cell Mol Life Sci. 2019;76(9):1779–94.PubMedCrossRef
69.
Ely A, Moyo B, Arbuthnot P. Progress with developing use of gene editing to cure chronic infection with hepatitis B virus. Mol Ther. 2016;24(4):671–7.PubMedPubMedCentralCrossRef
70.
Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Seimiya T, et al. Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. Hepatology. 2019;69(5):1903–15.PubMedCrossRef
71.
Kao CC, Nie Y, Ren S, De Costa NTS, Pandey RK, Hong J, et al. Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules. Mol Ther - Nucleic Acids. 2022;27:335–48.PubMedCrossRef
72.
Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy. J Viral Hepat. 2021;28(5):817–25.PubMedCrossRef
73.
Vaillant A. Targeting subviral particles: a critical step in achieving HBV functional cure but where are we with current agents in clinical development? Viruses. 2022;14(6).
74.
Khanam A, Chua JV, Kottilil S. Immunopathology of chronic hepatitis B infection: role of innate and adaptive immune response in disease progression. Int J Mol Sci. 2021;22(11).
75.
Lang-Meli J, Neumann-Haefelin C, Thimme R. Immunotherapy and therapeutic vaccines for chronic HBV infection. Curr Opin Virol. 2021;51:149–57.PubMedCrossRef
76.
Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol. 2018;68(3):431–40.PubMedCrossRef
77.
Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol. 2015;62(6):1237–45.PubMedPubMedCentralCrossRef
78.
Daffis S, Balsitis S, Chamberlain J, Zheng J, Santos R, Rowe W, et al. Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the Woodchuck model of chronic hepatitis B. Hepatology. 2021;73(1):53–67.PubMedCrossRef
79.
Agarwal K, Afdhal N, Coffin C, Fung S, Dusheiko G, Foster G, Elkhashab M, Tam E, Ramji A, Iyer R, et al. Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients. J Hepatol. 2020;73:S125.
80.
Yuen MF, Chen CY, Liu CJ, Jeng WJ, Elkhashab M, Coffin CS, Kim W, Greenbloom S, Ramji A, Lim YS, Kim YJ, Fung SK, Kim DJ, Jang JW, Lee KS, Iyer RP, Macfarlane C, Jackson K, Locarnini SA, Chan HLY, Afdhal NH. A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B. Liver Int. 2023;43(1):77–89.PubMedCrossRef
81.
Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138(2):682-U348.PubMedCrossRef
82.
Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019;71(5):900–7.PubMedCrossRef
83.
Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad Med J. 2013;89(1051):294–304.PubMedCrossRef
84.
Bohne F, Chmielewski M, Ebert G, Wiegmann K, Kurschner T, Schulze A, et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology. 2008;134(1):239–47.PubMedCrossRef
85.
Krebs K, Bottinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology. 2013;145(2):456–65.PubMedCrossRef
86.
Meng F, Zhao J, Tan AT, Hu W, Wang SY, Jin J, et al. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hepatol Int. 2021;15(6):1402–12.PubMedCrossRef
87.
88.
89.
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, et al. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother. 2020;16(2):388–99.PubMedCrossRef
90.
Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology. 2019;157(1):227-+.PubMedCrossRef
91.
Yoshida O, Akbar SMF, Imai Y, Sanada T, Tsukiyama-Kohara K, Miyazaki T, et al. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study. Hepatol Res. 2023;53(3):196–207.PubMedCrossRef
92.
Michler T, Kosinska AD, Festag J, Bunse T, Su J, Ringelhan M, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology. 2020;158(6):1762-75 e9.PubMedCrossRef
Metadata
Title
Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B
Authors
Harish Gopalakrishna
Marc G. Ghany
Publication date
10-02-2024
Publisher
Springer US
Keyword
Hepatitis B
Published in
Current Hepatology Reports / Issue 2/2024
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-024-00652-9

Other articles of this Issue 2/2024

Current Hepatology Reports 2/2024 Go to the issue

Review

When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?

Review

A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators

Review

Management of Hepatitis B in Pregnancy

Review

Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts

Review

Hepatitis B Virus Elimination Strategies

Review

Treatment of Gastric Varices
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits